Stocks Health care NTLA
NASDAQ · Health careIntellia Therapeutics, Inc. (NTLA)
Intellia Therapeutics, Inc. brought in $59.5M of revenue over the twelve months to June 30, 2026, up 12.6% from a year earlier. It posted a net loss of $400M. In fiscal 2025 capital spending exceeded operating cash flow by $395.9M. At June 30, 2026 it held $106.1M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 6, 2026.
What Intellia Therapeutics, Inc. does
Intellia Therapeutics, Inc. is registered with the SEC under industry code SIC 2835 (In Vitro & In Vivo Diagnostic Substances). Its shares trade on NASDAQ under the ticker NTLA.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $67.7M | -$412.7M | -$3.81 | -$395.9M |
| 2024 | $57.9M | -$519M | -$5.25 | -$354.7M |
| 2023 | $36.3M | -$481.2M | -$5.42 | -$408.1M |
| 2022 | $52.1M | -$474.2M | -$6.16 | -$346.8M |
| 2021 | $33.1M | -$267.9M | -$3.78 | -$237.8M |
| 2020 | $58M | -$134.2M | -$2.40 | -$53.5M |
Latest SEC filings
What Intellia Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 8, 2026
- September 4, 2026
- August 7, 2026Passive stake (5% or more) SCHEDULE 13G
- August 6, 2026Quarterly report 10-Q · period to June 30, 2026
- August 6, 2026
- June 15, 2026
- June 10, 2026
- May 11, 2026Quarterly report 10-Q · period to March 31, 2026
- May 11, 2026
- April 30, 2026
Questions about NTLA
What does Intellia Therapeutics, Inc. do?
Intellia Therapeutics, Inc. is registered with the SEC under industry code SIC 2835 (In Vitro & In Vivo Diagnostic Substances). Its shares trade on NASDAQ under the ticker NTLA.
Is Intellia Therapeutics, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $400M on revenue of $59.5M.
How much revenue does Intellia Therapeutics, Inc. make?
Over the twelve months to June 30, 2026 Intellia Therapeutics, Inc. reported revenue of $59.5M. That is 12.6% more than a year earlier.
When did Intellia Therapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 6, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the investor disclosure from September 8, 2026.
Similar companies
Follow NTLA
Get an email when Intellia Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow NTLA: get an email when it filesWhere the numbers come from
Financial figures are the values Intellia Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.